nach oben

Erschienen in:

19.06.2020 | Epidemiology

Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population

verfasst von: Nupur Rani Howlader, Md. Mostafizur Rahman, Md. Amir Hossain, Razia Sultana, Syed Mozammel Hossain, Md. Abdul Mazid, Md. Mustafizur Rahman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Genetic polymorphisms in DNA repair genes, XRCC1 (Arg399Gln) and XRCC3 (Thr241Met), may affect their DNA repair capacity leading to individual variation in breast cancer susceptibility among Bangladeshi females.

Methods

The case–control study comprised 121 breast cancer patients and 133 healthy controls. Genomic DNA isolated from peripheral blood was genotyped for target SNPs using PCR-RFLP method.

Results

For XRCC1, heterozygous Arg/Gln and homozygous Gln/Gln genotypes showed 1.78-fold (95% CI 1.0084 to 3.1442, p = 0.0467) and 2.41-fold (95% CI 1.0354 to 5.5914, p = 0.0413) increased risk of breast cancer, respectively, when compared with Arg/Arg genotype. The presence of any XRCC1 Gln showed association with 1.93-fold increased risk. The variant Gln allele was associated with increased risk of breast cancer (95% CI 1.1885 to 2.6805, p = 0.0052). For XRCC3, Thr/Met heterozygous and combined Thr/Met + Met/Met genotypes were associated with 1.85-fold (95% CI 1.0815 to 3.1834, p = 0.0248) and 1.89-fold (95% CI 1.1199 to 3.1908, p = 0.0171) higher risk, respectively, compared to Thr/Thr genotypes. The variant Met allele showed significant association with increased breast cancer susceptibility. Among cases genotype frequencies were significantly different in patients with age 55 or above, and with menopause and diabetes.

Conclusion

XRCC1 (Arg399Gln) and XRCC3 (Thr241Met) polymorphisms may be associated with increased breast cancer risk in Bangladeshi females.

Nur mit Berechtigung zugänglich

Ferlay J, Ervik M, Lam F et al (2018) Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon

McGuire A, Brown JAL, Malone C et al (2015) Effects of age on the detection and management of breast cancer. Cancers (Basel) 7:908–929

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMed

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J cancer 136:E359–E386PubMed

Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291:1284–1289PubMed

Kubota Y, Nash RA, Klungland A et al (1996) Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 15:6662–6670PubMedPubMedCentral

Tudek B (2007) Base excision repair modulation as a risk factor for human cancers. Mol Asp Med 28:258–275

Shen H, Wang X, Hu Z et al (2004) Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population. Cancer Lett 206:51–58PubMed

Figueiredo JC, Knight JA, Briollais L et al (2004) Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Prev Biomark 13:583–591

10.

Webb PM, Hopper JL, Newman B et al (2005) Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Prev Biomark 14:319–323

11.

Khlifi R, Kallel I, Hammami B et al (2014) DNA repair gene polymorphisms and risk of head and neck cancer in the Tsunisian population. J Oral Pathol Med 43:217–224PubMed

12.

Duell EJ, Millikan RC, Pittman GS et al (2001) Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Prev Biomark 10:217–222

13.

Han J, Hankinson SE, De Vivo I et al (2003) A prospective study of XRCC1 haplotypes and their interaction with plasma carotenoids on breast cancer risk. Cancer Res 63:8536–8541PubMed

14.

Smith TR, Levine EA, Perrier ND et al (2003) DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Prev Biomark 12:1200–1204

15.

Shen J, Gammon MD, Terry MB et al (2005) Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk. Cancer Epidemiol Prev Biomark 14:336–342

16.

Patel AV, Calle EE, Pavluck AL et al (2005) A prospective study of XRCC1(X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res 7:R1168. https://doi.org/10.1186/bcr1355 CrossRefPubMedPubMedCentral

17.

Bu D, Tomlinson G, Lewis CM et al (2006) An intronic polymorphism associated with increased XRCC1 expression, reduced apoptosis and familial breast cancer. Breast Cancer Res Treat 99:257–265PubMed

18.

Thyagarajan B, Anderson KE, Folsom AR et al (2006) No association between XRCC1 and XRCC3 gene polymorphisms and breast cancer risk: Iowa Women’s Health Study. Cancer Detect Prev 30:313–321PubMed

19.

Sangrajrang S, Schmezer P, Burkholder I et al (2007) The XRCC3 Thr241Met polymorphism and breast cancer risk: a case–control study in a Thai population. Biomarkers 12:523–532PubMed

20.

Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103:209–217PubMed

21.

Economopoulos KP, Sergentanis TN (2010) XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 121:439–443PubMed

22.

World Medical Association (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194. https://doi.org/10.1001/jama.2013.281053

23.

Daly AK, Monkman SC, Smart J et al (1998) Analysis of cytochrome P450 polymorphisms. Cytochrome P450 protocols. Springer, New York, pp 405–422

24.

Saiki RK, Gelfand DH, Stoffel S et al (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487–491PubMed

25.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7–30PubMed

26.

Landi S (2009) Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat Res 681:299–307PubMed

27.

Chu D, Kohlmann W, Adler DG (2010) Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP J Pancreas 11:203–212

28.

Lowenfels AB, Maisonneuve P (2003) Environmental factors and risk of pancreatic cancer. Pancreatology 3:1–8PubMed

29.

Wong H, Wilson DM (2005) XRCC1 and DNA polymerase β interaction contributes to cellular alkylating-agent resistance and single-strand break repair. J Cell Biochem 95:794–804PubMed

30.

Liu N, Lamerdin JE, Tebbs RS et al (1998) XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1:783–793PubMed

31.

Pierce AJ, Johnson RD, Thompson LH, Jasin M (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13:2633–2638PubMedPubMedCentral

32.

Smolarz B, Makowska M, Samulak D et al (2014) Single nucleotide polymorphisms (SNPs) of ERCC2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women. Tumor Biol 35:3495–3502

33.

Han J, Haiman C, Niu T et al (2009) Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Breast Cancer Res Treat 115:613–622PubMed

34.

Wang L, Wang G, Lu C et al (2012) Contribution of the-160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies. PLoS ONE 7:e40219PubMedPubMedCentral

35.

Jeanes A, Gottardi CJ, Yap AS (2008) Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27:6920PubMedPubMedCentral

36.

Popanda O, Tan X-L, Ambrosone CB et al (2006) Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol Prev Biomark 15:1048–1050

37.

Kuschel B, Auranen A, McBride S et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11:1399–1407PubMed

38.

Rao KS, Paul A, Kumar ASA et al (2014) Allele and genotype distributions of DNA repair gene polymorphisms in South Indian healthy population. Biomark Cancer 6:BIC-S19681

39.

Takeshita H, Fujihara J, Yasuda T, Kimura-Kataoka K (2015) Worldwide distribution of four SNPs in X-ray and repair and cross-complementing group 1 (XRCC1). Clin Transl Sci 8:347–350PubMed

40.

Goričar K, Kovač V, Dolžan V (2017) Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Sci Rep 7:46537PubMedPubMedCentral

41.

Sterpone S, Mastellone V, Padua L et al (2010) Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women. J Cancer Res Clin Oncol 136:631–636PubMed

42.

Chacko P, Rajan B, Joseph T et al (2005) Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat 89:15–21PubMed

43.

Luo H, Li Z, Qing Y et al (2014) Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J Cancer Prev 15:1133–1140PubMed

44.

Ramadan RA, Desouky LM, Elnaggar MA et al (2014) Association of DNA repair genes XRCC1 (Arg399Gln),(Arg194Trp) and XRCC3 (Thr241Met) polymorphisms with the risk of breast cancer: a case–control study in Egypt. Genet Test Mol Biomark 18:754–760

45.

Shadrina AS, Ermolenko NA, Boyarskikh UA et al (2016) Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case–control study. Clin Exp Med 16:21–28PubMed

46.

Syamala VS, Syamala V, Sreedharan H et al (2009) Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report. Pathol Oncol Res 15:389PubMed

47.

Smolarz B, Michalska MM, Samulak D et al (2019) Polymorphism of DNA repair genes in breast cancer. Oncotarget 10:527PubMedPubMedCentral

48.

Romanowicz H, Smolarz B, Baszczyński J et al (2010) Genetics polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the Polish population. Pol J Pathol 61:206–212PubMed

49.

Macías-Gómez NM, Peralta-Leal V, Meza-Espinoza JP et al (2015) Polymorphisms of the XRCC1 gene and breast cancer risk in the Mexican population. Fam Cancer 14:349–354PubMed

50.

Romanowicz H, Pyziak Ł, Jabłoński F et al (2017) Analysis of DNA repair genes polymorphisms in breast cancer. Pathol Oncol Res 23:117–123PubMed

51.

Roberts MR, Shields PG, Ambrosone CB et al (2011) Single-nucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study. Carcinogenesis 32:1223–1230PubMedPubMedCentral

52.

Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608PubMed

53.

Lunn RM, Langlois RG, Hsieh LL et al (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin a variant frequency. Cancer Res 59:2557–2561PubMed

54.

Duell EJ, Wiencke JK, Cheng T-J et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965–971PubMed

55.

Al Mutairi FM, Alanazi M, Shalaby M et al (2013) Association of XRCC1 gene polymorphisms with breast cancer susceptibility in Saudi patients. Asian Pac J Cancer Prev 14:3809–3813PubMed

56.

Hussien Y, Gharib A, Karam R, Elsawy W (2011) Impact of DNA repair gene polymorphisms (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients. Bull Egypt Soc Physiol Sci 31:91–106

57.

Metsola K, Kataja V, Sillanpää P et al (2005) XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study. Breast Cancer Res 7:R987PubMedPubMedCentral

58.

Zipprich J, Terry MB, Brandt-Rauf P et al (2010) XRCC1 polymorphisms and breast cancer risk from the New York Site of the breast cancer family Registry: a family-based case-control study. J Carcinog 9:4PubMedPubMedCentral

59.

Kim S-U, Park SK, Yoo K-Y et al (2002) XRCC1 genetic polymorphism and breast cancer risk. Pharmacogenet Genom 12:335–338

60.

Moghaddam AS, Nazarzadeh M, Moghaddam HS et al (2016) XRCC1 gene polymorphisms and breast cancer risk: a systematic review and meta-analysis study. Asian Pac J Cancer Prev 17:323–335

61.

Wu K, Su D, Lin K et al (2011) XRCC1 Arg399Gln gene polymorphism and breast cancer risk: a meta-analysis based on case-control studies. Asian Pac J Cancer Prev 12:2237–2243PubMed

62.

Saadat M (2010) Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat 124:785–791PubMed

63.

Zdzienicka MZ (1999) Mammalian X-ray-sensitive mutants which are defective in non-homologous (illegitimate) DNA double-strand break repair. Biochimie 81:107–116PubMed

64.

Thacker J, Zdzienicka MZ (2004) The XRCC genes: expanding roles in DNA double-strand break repair. DNA Repair (Amst) 3:1081–1090

65.

Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ (2000) XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res Repair 459:89–97

66.

Richardson C (2005) RAD51, genomic stability, and tumorigenesis. Cancer Lett 218:127–139PubMed

67.

García-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119:376PubMed

68.

Bastos HN, Antao MR, Silva SN et al (2009) Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk. Thyroid 19:1067–1075PubMed

69.

Sturgis EM, Zhao C, Zheng R, Wei Q (2005) Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope 115:938–945PubMed

70.

Qureshi Z, Mahjabeen I, Baig RM, Kayani MA (2014) Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan. Asian Pac J Cancer Prev 15:10225–10229PubMed

71.

Smolarz B, Makowska M, Samulak D et al (2015) Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and triple-negative breast cancer in Polish women. Clin Exp Med 15:151–157PubMed

72.

Krupa R, Synowiec E, Pawlowska E et al (2009) Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer. Exp Mol Pathol 87:32–35PubMed

73.

Sobczuk A, Romanowicz-Makowska H, Fiks T et al (2009) XRCC1 and XRCC3 DNA repair gene polymorphisms in breast cancer women from the Lodz region of Poland. Polish J Pathol 60:76–80

74.

Su C-H, Chang W-S, Hu P-S et al (2015) Contribution of DNA double-strand break repair gene XRCC3 genotypes to triple-negative breast cancer risk. Cancer Genom-Proteom 12:359–367

75.

Loizidou MA, Michael T, Neuhausen SL et al (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat 112:575–579PubMed

76.

Ali AM, AbdulKareem H, Al Anazi M et al (2016) Polymorphisms in DNA repair gene XRCC3 and susceptibility to breast cancer in Saudi females. Biomed Res Int. https://doi.org/10.1155/2016/8721052 CrossRefPubMedPubMedCentral

77.

Devi KR, Ahmed J, Narain K et al (2017) DNA repair mechanism gene, XRCC1A (Arg194Trp) but not XRCC3 (Thr241Met) polymorphism increased the risk of breast cancer in premenopausal females: a case–control study in northeastern Region of India. Technol Cancer Res Treat 16:1150–1159PubMedPubMedCentral

78.

Al ZMS, Zavaglia K, Mazanti C et al (2017) Polymorphisms and mutations in GSTP1, RAD51, XRCC1 and XRCC3 genes in breast cancer patients. Int J Biol Markers 32:337–343

79.

Jordan S, Lim L, Vilainerun D et al (2009) Breast cancer in the Thai Cohort Study: an exploratory case-control analysis. The Breast 18:299–303PubMed

Titel: Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population
verfasst von: Nupur Rani Howlader
Md. Mostafizur Rahman
Md. Amir Hossain
Razia Sultana
Syed Mozammel Hossain
Md. Abdul Mazid
Md. Mustafizur Rahman
Publikationsdatum: 19.06.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05738-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients

Re: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients

The bottom line for lesion localization in breast cancer

Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie